Molecular Testing for Lower Genital Tract Infections Overused, Study Finds

Major Finding: The use of unrecommended molecular tests for lower genital tract infections increased total molecular test spending by 29%, compared with the cost of recommended molecular tests alone.

Data Source: Laboratory claims from 82,443 patients in a large national insurance database from the year 2008.

Disclosures: Dr. Eckert said that she had no relevant financial conflicts to disclose.